RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer
OBJECTIVES: Primary * To assess the local recurrence (LR) rate with breast-conservation in patients with multiple ipsilateral primary breast cancer (MIBC). Secondary * To examine the conversion rate to mastectomy secondary to persistent positive margins; poor cosmesis within the first year of attempting breast-conservation surgery (BCS) or inability to satisfy the radiation dose constraints on the boost to the lumpectomy bed of each site of disease. * To assess whether patients who did not undergo re-excision for close margins (\< 2 mm) have a higher local recurrence (LR) rate than patients for whom negative margins were achieved. * To assess patient's perception of cosmesis and incidence of breast lymphedema. * To assess incidence of breast lymphedema * To examine the type and severity of adverse effects of breast conserving surgery and radiation for women with multiple ipsilateral primary breast cancer (MIBC). * To examine the radiation-related side effects of whole-breast radiation with a boost to 1 large or \> 1 lumpectomy site. OUTLINE: This is a multicenter study. Patients undergo breast-conserving surgery (BCS) with all lesions resected to negative margins using 1 lumpectomy or 2-3 separate lumpectomy incisions at the discretion of the surgeon. Patients receive adjuvant chemotherapy and/or endocrine therapy at the discretion of the treating medical oncologist based on tumor characteristics.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
Local Recurrence
Local recurrence(LR) defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall assessed up to 5 years. The estimated 5-year cumulative incidence of LR will be reported as a percentage of patients expected to experience a LR at 5 years.
Time frame: 5 years
Conversion Rate to Mastectomy
The conversion rate to mastectomy secondary to persistent positive margins; poor cosmesis within the first year of attempting BCS; or inability to satisfy the radiation dose constraints on the boost to the lumpectomy bed of each site of disease.
Time frame: 5 years
Severity of Adverse Effects
Severity of adverse effects of breast-conserving surgery and radiation as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be reported as the percentage of patients that experienced a grade 3 or higher adverse event.
Time frame: 17 monhts
Radiation-related Side Effects
Radiation-related side effects of whole-breast radiation with a boost to 1 large or \> 1 lumpectomy site as assessed by NCI CTCAE version 4.0.
Time frame: 17 months
Patient's Perception of Cosmesis
Patient's perception of cosmesis will be assessed at their initial post-operative visit as well as 24 months following completion of WBI using the BREAST-Q subscales: satisfaction with breasts, satisfaction with overall outcome, and physical well-being. Patients registered after surgery will not partake in the pre-operative assessment but will be asked to complete subsequent cosmesis surveys. The total score for each of these subscales will be determined using the BREAST-Q scoring module (http://www.mskcc.org/mskcc/shared/Breast-Q/scoreBQ.html). The BREAST-Q has multiple domains, and each domain score is obtained by transforming the raw scale item responses with the Q-Score software program. Each domain results in an independent score from 0 to 100 (higher scores indicate greater satisfaction or quality of life).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
270
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States
Epic Care-Dublin
Dublin, California, United States
Bay Area Breast Surgeons, Incorporated
Emeryville, California, United States
Epic Care Partners in Cancer Care
Emeryville, California, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Contra Costa Regional Medical Center
Martinez, California, United States
Alta Bates Summit Medical Center-Summit Campus
Oakland, California, United States
Bay Area Tumor Institute
Oakland, California, United States
...and 340 more locations
Time frame: 24 months